TSLA
Tesla
-- 417.410 NVDA
NVIDIA
-- 137.490 MSTR
MicroStrategy
-- 302.960 BA
Boeing
-- 176.550 RGTI
Rigetti Computing
-- 17.0000 
NEWS PM
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-based digital pathology confirmed denifanstat's strong anti-fibrotic activity, especially in portal and peri-portal regions. Preclinical data also demonstrated FASN inhibitor's potential in reducing atherosclerosis, cholesterol, and inflammatory markers, suggesting broader cardiometabolic benefits.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
102339692 : good results why keep dropping
Jaguar8 OP 102339692 : Always remember, shorts are in all stocks. If it doesn’t have volume, shorts will kill it no matter how good the news is.
102339692 Jaguar8 OP :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
OooUpup : I agree. No vol no trajectory but how much vol is good enough to launch?
Jaguar8 OP OooUpup : Depends on the float too